Variability of on-treatment platelet reactivity in patients on clopidogrel

References

• Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233–238
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–2913
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527–533
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1607–1621
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630–1636
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009;119:237–242
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. Jama 2010;303:754–762
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5–10
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404–1411
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 2012;59:2159–2164
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100–2109
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. Jama 2011;305:1097–1105
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012;18:5197–5214
   PubMed Web of Science ®Google Scholar
• Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: Definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18:5344–5361
   PubMed Web of Science ®Google Scholar
• Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010;56:839–847
   Google Scholar
• Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008;52:1826–1833
   PubMed Web of Science ®Google Scholar
• Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, Kastrati A, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011;105:107–112
   PubMed Web of Science ®Google Scholar
• Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. High-Dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) Study. JACC Cardiovasc Interv 2013;6:169–179
   Google Scholar
• Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. Am Heart J 2009;157:818–824, 24 e1
   PubMed Web of Science ®Google Scholar
• King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261–295
   PubMed Web of Science ®Google Scholar
• Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, et al. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501–2555
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Willheim M, Hubl W, Wojta J, Huber K. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter? Thromb Haemost 2012;107:538–544
   PubMed Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474–2483
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239–247
   PubMed Web of Science ®Google Scholar
• Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996;94:279–285
   PubMed Web of Science ®Google Scholar
• Palmerini T, Barozzi C, Tomasi L, Sangiorgi D, Marzocchi A, De Servi S, Ortolani P, Reggiani LB, Alessi L, Lauria G, et al. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thromb Res 2010;125:309–314
   PubMedGoogle Scholar
• Althoff TF, Fischer M, Langer E, Ziemer S, Baumann G. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res 2010;125:e190–e196
   PubMed Web of Science ®Google Scholar
• Funck-Jensen KL, Dalsgaard J, Grove EL, Hvas AM, Kristensen SD. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets 2012; Dec 5 [epub ahead of print]
   Google Scholar
• Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743–749
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Brozovic I, Grove EL, Kristensen SD, Willheim M, Hubl W, Huber K. Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thromb Haemost 2011;106:182–184
   PubMedGoogle Scholar
• Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010;3:828–835
   PubMed Web of Science ®Google Scholar
• Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005;35:476–481
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008;99:215–222
   PubMed Web of Science ®Google Scholar
• Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, Bailey WL, Tantry US, Gurbel PA. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531–533
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, et al. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy. JAMA 2012;308:1785–94 . doi: 10.1001/jama.2012.17312
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557–1563
   PubMed Web of Science ®Google Scholar
• Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, Kastrati A, Sibbing D. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011;161:605–610
   Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169–174
   PubMedGoogle Scholar
• Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312–2317
   PubMed Web of Science ®Google Scholar
• Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Levy N, Maillard L, Barragan P, Dignat-George F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:1511–1515
   PubMed Web of Science ®Google Scholar
• Schafer A, Weinberger S, Flierl U, Eigenthaler M, Stork S, Walter U, Ertl G, Bauersachs J. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008;100:618–625
   PubMed Web of Science ®Google Scholar
• Schafer A, Flierl U, Kossler J, Seydelmann N, Kobsar A, Stork S, Bauersachs J. Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. Thromb Haemost 2011;106:141–148
   PubMedGoogle Scholar
• Davi G, Ganci A, Averna M, Giammarresi C, Barbagallo C, Catalano I, Cala A, Notarbartolo A. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost 1995;74:1015–1019
   Google Scholar
• Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974;290:434–438
   PubMed Web of Science ®Google Scholar
• Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci 1994;55:1815–1821
   Google Scholar
• Zafar MU, Paz-Yepes M, Shimbo D, Vilahur G, Burg MM, Chaplin W, Fuster V, Davidson KW, Badimon JJ. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. Eur Heart J 2010;31:1573–1582
   PubMed Web of Science ®Google Scholar
• Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: Results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012;125:3201–3210
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Ten Berg JM. Platelet reactivity over time: Solid as a rock or not durable? Thromb Haemost 2011;105:3–4
   Google Scholar
• Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123–1125
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hubl W, Wojta J, Huber K. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011;106:230–239
   Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010;103:1210–1217
   PubMed Web of Science ®Google Scholar
• Schumacher WA, Bostwick JS, Ogletree ML, Stewart AB, Steinbacher TE, Hua J, Price LA, Wong PC, Rehfuss RP. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J Pharmacol Exp Ther 2007;322:369–377
   PubMedGoogle Scholar
• Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010;104:571–581
   PubMed Web of Science ®Google Scholar